Form 4: Keros Therapeutics Insider Sells Over 1,700 Shares and Closes Put Option Positions

ADAR1 Capital Management, a 10% owner and director of Keros Therapeutics, Inc., reported the disposition of 1,700 shares of common stock and the closing of several put option positions on June 20, 2025.

Summary

• ADAR1 Capital Management, LLC, along with related entities ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, reported transactions in Keros Therapeutics, Inc. (KROS) securities.
• On June 20, 2025, 100 shares of common stock were disposed of at a price of $60 per share, leaving 4,392,637 shares indirectly beneficially owned by ADAR1 Partners, LP.
• An additional 1,400 shares of common stock were disposed of at a price of $70 per share on June 20, 2025, resulting in 4,391,237 shares indirectly beneficially owned by ADAR1 Partners, LP.
• Furthermore, 200 shares of common stock were disposed of at a price of $70 per share on June 20, 2025, with 743,358 shares indirectly beneficially owned by Spearhead Insurance Solutions IDF, LLC.
• The reporting persons also disposed of put options (right to sell) on June 20, 2025, with strike prices of $60 and $70, covering a total of 1,700 underlying common shares, resulting in zero derivative securities beneficially owned following these transactions.
• The put options had various exercisable dates (October 1, 2024, and October 2, 2024) and an expiration date of June 20, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling of common stock by a significant owner and director, which can be interpreted as a lack of confidence. The closing of put option positions is more ambiguous but does not offset the negative signal from the stock sales.

Negatives

• The disposition (sale) of common stock by a 10% owner and director can be perceived as a negative signal by investors, potentially indicating a lack of confidence in the company's near-term prospects.
• The sale of shares at prices of $60 and $70, while not necessarily below market, represents a reduction in the insider's direct equity exposure.

Risks

• The reported insider selling could lead to negative market sentiment, potentially impacting Keros Therapeutics' stock price.
• The disclaimer of beneficial ownership by the reporting persons, except to the extent of their pecuniary interest, highlights the complex ownership structure and potential for limited direct accountability for all shares held by associated entities.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports specific insider transactions and does not provide broader industry context or trends. It reflects individual investment decisions by a significant shareholder and director within the biotechnology sector.

Related Party Transactions

• The transactions involve ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, who are identified as a 10% owner and director of Keros Therapeutics, Inc. These dispositions of common stock and derivative securities by an insider constitute related party transactions.

Stakeholder Impact

• Shareholders may view the insider selling as a bearish signal, potentially leading to a decrease in investor confidence and a negative impact on the stock price.
• The transactions do not directly impact employees, customers, suppliers, or creditors, but a decline in stock price could indirectly affect employee stock options or overall company valuation.

Key Dates

Keywords

Keros Therapeutics, KROS, SEC Form 4, Insider Trading, Stock Sale, Put Option, ADAR1 Capital Management, Beneficial Ownership, Equity Disposition